Meridian Bioscience, Inc. has announced its increased commitment to the global fight against COVID-19 by making available zero cost samples of the company’s proprietary technologies to developers and manufacturers of molecular assays for COVID-19 detection.

By utilizing Meridian’s specialized enzyme formulations (Fast RT-qPCR Mix and Lyo-Ready 1-Step RT-qPCR Mix), Meridian hopes that diagnostic companies around the world will be able to develop COVID-19 detection assays with greater sensitivity, faster run-times and formatted for high throughput testing.

To help expedite such development, Meridian is pleased to provide from stock its specialized enzyme formulations to manufacturers of a COVID-19 molecular detection assay at no cost. Following the successful development of a COVID-19 detection assay or kit, it is Meridian’s commitment to continue to manufacture and supply its propriety formulations at commercial scale to meet the global demand.    

In a statement earlier today Todd Howren, Ph.D., Vice President of Global Sales of Life Science said the following, “We are excited to partner with molecular diagnostic companies around the world in our common fight against COVID-19. Many Molecular Diagnostic companies in the United States, China, and Europe have already incorporated Meridian’s technologies in their assays.

By making these master mixes available at no charge for initial testing and development, we hope that we can accelerate the availability of new COVID-19 test kits and that faster, more economical and more sensitive assays will be developed in the fight against this deadly pathogen.”

Meridian is committed to supplying solutions to the diagnostic industry during times of a pandemic health crisis. For more information on receiving an initial evaluation and testing sample, please use the Request Information button below.